An official website of the United States government
Home
Name
Imbruvica
Alternate Names
imbrutinib
Abbreviations
None
Category
Chemotherapy
Subcategory
Bruton's tyrosine kinase (BTK) inhibitor
NSC Number
None
Primary Site
None
Histology
Marginal zone lymphoma
Remarks
August 24, 2022, the FDA approved ibrutinib (Imbruvica) for pediatric patients ≥ 1 year of age with chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension. DO NOT CODE AS TREATMENT WHEN GIVEN FOR cGVHD
8/31/2018: The Janssen Pharmaceutical Companies of Johnson & Johnson announced the FDA approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of Waldenström’s macroglobulinemia
1/27/2017: FDA approved the drug Imbruvica (imbrutinib) for the treatment of patients with relapsed/refractory marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy.
8/31/2018: The Janssen Pharmaceutical Companies of Johnson & Johnson announced the FDA approval of Imbruvica (ibrutinib) in combination with rituximab for the treatment of Waldenström’s macroglobulinemia
1/27/2017: FDA approved the drug Imbruvica (imbrutinib) for the treatment of patients with relapsed/refractory marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy.
Coding
This drug should be coded
